High Fiber Diet for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether a high-fiber diet can enhance the effects of immune checkpoint inhibitors—medicines that help the immune system fight cancer—in people with non-small cell lung cancer (NSCLC). Participants will either maintain their usual diet or receive guidance to increase fiber intake as part of a dietary intervention. The goal is to determine if more fiber can improve the effectiveness of cancer treatment. Individuals with NSCLC who are on immune checkpoint inhibitors and can eat solid foods may be suitable candidates for this trial. As an unphased trial, this study provides a unique opportunity to contribute to innovative research that could improve cancer treatment outcomes.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It might be best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this dietary intervention is safe for patients with non-small cell lung cancer?
Research shows that a high-fiber diet is generally safe and beneficial. Studies have found a link between increased fiber intake and a lower risk of lung cancer. Specifically, individuals who consumed a lot of fiber had a 33% lower chance of developing lung cancer.
Other research suggests that fiber might improve outcomes for various types of cancer. Some studies found that patients who consumed more fiber responded better to certain cancer treatments.
Overall, most people can increase their fiber intake without issues. No major reports of serious side effects from consuming more fiber exist. However, some individuals might experience mild digestive issues, such as bloating or gas, when they first increase their fiber intake. Gradually adding more fiber to the diet can help reduce these effects.12345Why are researchers excited about this trial?
Researchers are excited about the high fiber diet being studied for lung cancer because it offers a non-drug approach to potentially improve patient outcomes. Unlike the standard treatments for lung cancer, which often involve chemotherapy, radiation, or targeted therapies, this dietary intervention focuses on increasing fiber intake, which is believed to enhance gut health and possibly boost the immune response. The method is simple, involving dietary changes and counseling, making it an accessible option that could complement existing treatments. This novel approach might provide additional benefits without the side effects typically associated with traditional cancer treatments.
What evidence suggests that this dietary intervention is effective for non-small cell lung cancer?
Research shows that a high-fiber diet can help lung cancer patients respond better to treatment. In this trial, participants in the intervention group will receive counseling to increase their total fiber intake. Studies have found that dietary advice helps patients maintain stable weight and a healthy diet, which can improve treatment outcomes. Increased fiber intake is also linked to better responses to immune checkpoint inhibitors, a common treatment for non-small cell lung cancer. Additionally, a high-fiber diet is associated with a lower risk of developing lung cancer, regardless of other risk factors. Early findings suggest that a high-fiber diet might also enhance responses to standard immunotherapy for other cancer types.45678
Who Is on the Research Team?
Bertrand Routy, MD,PhD
Principal Investigator
CHUM
Are You a Good Fit for This Trial?
This trial is for adults over 18 with confirmed non-small cell lung cancer (NSCLC) who are being treated with standard immune checkpoint inhibitors and can eat solid foods. It's not suitable for those with severe dietary allergies or psychiatric/substance abuse issues that could affect participation.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive standard-of-care immune checkpoint inhibitor (ICI) therapy alone or in combination with a dietary intervention
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Dietary Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Centre hospitalier de l'Université de Montréal (CHUM)
Lead Sponsor